Table 2.
Univariate and multivariate analysis on PFS
| Variable | Univariate |
Multivariate |
||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age at AI (yr) | ||||
| 20-39 | 1 | - | ||
| 40-49 | 0.95 (0.50-1.77) | 0.859 | - | |
| ≥ 50 | 1.05 (0.42-2.62) | 0.918 | - | - |
| OFS modality | ||||
| BSO | 1 | - | ||
| GnRHa | 1.41 (0.79-2.55) | 0.249 | - | - |
| Pathology | ||||
| IDC | 1 | - | ||
| Others | 0.64 (0.22-1.80) | 0.394 | - | - |
| Intrinsic subtype | ||||
| Luminal A | 1 | 1 | ||
| Luminal B | 1.59 (1.02-2.49) | 0.041 | 1.67 (1.08-2.60) | 0.022 |
| Disease status | ||||
| MBC at primary Dx | 1 | - | ||
| Recurred | 0.82 (0.47-1.42) | 0.468 | - | - |
| Extent of disease | ||||
| Bone/Soft tissue | 1 | - | ||
| Visceral | 1.48 (0.85-2.58) | 0.168 | - | - |
| AI | ||||
| Letrozole | 1 | - | ||
| Anastrozole | 2.39 (0.83-6.88) | 0.107 | - | - |
| Line of AI | ||||
| 1st line | 1 | 1 | ||
| 2nd line | 1.51 (0.77-2.98) | 0.232 | 1.73 (0.87-3.44) | 0.120 |
| ≥ 3rd line | 3.01 (1.48-6.13) | 0.002 | 3.24 (1.59-6.59) | 0.001 |
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; AI, aromatase inhibitor; OFS, ovarian function suppression; BSO, bilateral salpingoophorectomy; GnRHa, gonadotropin-releasing hormone agonist; IDC, infiltrating ductal carcinoma; MBC, metastatic breast cancer; Dx, diagnosis.